January 20-24, 2025, Maui, Hawaii

Maui Derm 2025

Other Key Congresses - 2025

Poster icon

Pooled REMIX-1/-2 phase 3 data: Early and sustained symptom improvement with remibrutinib in chronic spontaneous urticaria

S. Saini, G. Mosnaim, A.G-Arnau, L. Li, El-D. Martzloff, A. Burciu, K. Lheritier, M. Metz
ePoster
Poster icon

Out-of-pocket expenses in patients with chronic spontaneous urticaria: Results from Urticaria Voices

T.A. Winders, J.A. Bernstein, T. Raftery, N.C-Rothe, J. McCarthy, P. Saraswat, P. Orfanos, R.K. Kohli, D. Patil, K. Weller
ePoster
Poster icon

Effect of remibrutinib on sleep and daily activities in patients with chronic spontaneous urticaria (CSU) up to week 52 in the REMIX-1/-2 studies

R. Snyder, Y. Bin, D. Merritt, S.F. Thomsen, A. Fukunaga, C. Field, S. Haemmerle, C-Ya. Chu, N. Seko, M. Metz
ePoster
Poster icon

Improvements in itch and hive symptoms with remibrutinib as early as week 1 in patients with chronic spontaneous urticaria (CSU) in REMIX-1/-2

M. Scarupa, S. Dinehart, X. Jiang, L. Finklea, J. Reed, Y.M. Ye, C. Field, S. Haemmerle, P. Wang, G. Sussman
ePoster
Poster icon

Effects of remibrutinib treatment on ambulatory blood pressure in adult patients with chronic spontaneous urticaria (CSU)

M. Palumbo, G. Mosnaim, U. Lippert, S. Haemmerle, M.F. Eigenmann, K. Lheritier, A. Zharkov, P. Machado, I. Rodriguez, M.G. Lebwohl
ePoster
Novartis logo
Cookie Settings
© Copyright 2025 Novartis Pharma AG